AIMP1 and central nervous system cancer: EMAP-II combined with anti-miR-330-3p and PKC-α activator significantly increased the permeability of BTB and enhanced the effects of DOX on inhibiting the cell viabilities and promoting the apoptosis of U87 glioma cells.